Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anti-cancer treatment

On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy

Research output: Contribution to journalArticle

Abstract

Lenvatinib is an emerging multi-kinase inhibitor with a preferential antiangiogenic activity, which has shown efficacy in the treatment of renal cell carcinoma, differentiated thyroid cancer and hepatocellular carcinoma. It inhibits vascular endothelial growth factor receptor family (VEGFR1-3), fibroblast growth factor receptor family (FGFR1-4), platelet-derived growth factor receptor-alpha (PDGFRα), tyrosine-kinase receptor (KIT) and rearranged during transfection receptor (RET). In this review we have evaluated the development from bench to bedside of lenvatinib. PubMed, MEDLINE and clinicaltrials.gov are the sources of data. Furthermore, the preclinical in vitro and in vivo data, as well as efficacy and toxicity results of lenvatinib in the clinic, are presented and discussed. Treatment with lenvatinib causes side effects (hypertension, proteinuria, fatigue and diarrhea), which are predominantly related to the inhibition of angiogenesis. For these reasons, the identification of biomarkers of efficacy and resistance to lenvatinib is a key challenge in order to select responsive patients. This review provides an overview on lenvatinib’s clinical use, perspectives and indications for future development.

Original languageEnglish
Pages (from-to)3847-3860
Number of pages14
JournalCancer Management and Research
Volume11
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Neoplasms
Thyroid Neoplasms
Receptor, Fibroblast Growth Factor, Type 3
Therapeutics
Vascular Endothelial Growth Factor Receptor
Information Storage and Retrieval
Receptor Protein-Tyrosine Kinases
Proteinuria
Renal Cell Carcinoma
PubMed
MEDLINE
Fatigue
Transfection
Hepatocellular Carcinoma
Diarrhea
Phosphotransferases
Biomarkers
lenvatinib
Hypertension
In Vitro Techniques

Keywords

  • Angiogenesis
  • Kinase inhibitors
  • Microvessel density
  • Tumors

ASJC Scopus subject areas

  • Oncology

Cite this

Lenvatinib, a molecule with versatile application : From preclinical evidence to future development in anti-cancer treatment. / On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy.

In: Cancer Management and Research, Vol. 11, 01.01.2019, p. 3847-3860.

Research output: Contribution to journalArticle

On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy 2019, 'Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anti-cancer treatment', Cancer Management and Research, vol. 11, pp. 3847-3860. https://doi.org/10.2147/CMAR.S188316
On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy. Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anti-cancer treatment. Cancer Management and Research. 2019 Jan 1;11:3847-3860. https://doi.org/10.2147/CMAR.S188316
On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy. / Lenvatinib, a molecule with versatile application : From preclinical evidence to future development in anti-cancer treatment. In: Cancer Management and Research. 2019 ; Vol. 11. pp. 3847-3860.
@article{89d1760affe84352b9d6b94bd1c31d7c,
title = "Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anti-cancer treatment",
abstract = "Lenvatinib is an emerging multi-kinase inhibitor with a preferential antiangiogenic activity, which has shown efficacy in the treatment of renal cell carcinoma, differentiated thyroid cancer and hepatocellular carcinoma. It inhibits vascular endothelial growth factor receptor family (VEGFR1-3), fibroblast growth factor receptor family (FGFR1-4), platelet-derived growth factor receptor-alpha (PDGFRα), tyrosine-kinase receptor (KIT) and rearranged during transfection receptor (RET). In this review we have evaluated the development from bench to bedside of lenvatinib. PubMed, MEDLINE and clinicaltrials.gov are the sources of data. Furthermore, the preclinical in vitro and in vivo data, as well as efficacy and toxicity results of lenvatinib in the clinic, are presented and discussed. Treatment with lenvatinib causes side effects (hypertension, proteinuria, fatigue and diarrhea), which are predominantly related to the inhibition of angiogenesis. For these reasons, the identification of biomarkers of efficacy and resistance to lenvatinib is a key challenge in order to select responsive patients. This review provides an overview on lenvatinib’s clinical use, perspectives and indications for future development.",
keywords = "Angiogenesis, Kinase inhibitors, Microvessel density, Tumors",
author = "{On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy} and Monica Capozzi and {De Divitiis}, Chiara and Alessandro Ottaiano and {Von Arx}, Claudia and Stefania Scala and Fabiana Tatangelo and Paolo Delrio and Salvatore Tafuto",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/CMAR.S188316",
language = "English",
volume = "11",
pages = "3847--3860",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Lenvatinib, a molecule with versatile application

T2 - From preclinical evidence to future development in anti-cancer treatment

AU - On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy

AU - Capozzi, Monica

AU - De Divitiis, Chiara

AU - Ottaiano, Alessandro

AU - Von Arx, Claudia

AU - Scala, Stefania

AU - Tatangelo, Fabiana

AU - Delrio, Paolo

AU - Tafuto, Salvatore

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Lenvatinib is an emerging multi-kinase inhibitor with a preferential antiangiogenic activity, which has shown efficacy in the treatment of renal cell carcinoma, differentiated thyroid cancer and hepatocellular carcinoma. It inhibits vascular endothelial growth factor receptor family (VEGFR1-3), fibroblast growth factor receptor family (FGFR1-4), platelet-derived growth factor receptor-alpha (PDGFRα), tyrosine-kinase receptor (KIT) and rearranged during transfection receptor (RET). In this review we have evaluated the development from bench to bedside of lenvatinib. PubMed, MEDLINE and clinicaltrials.gov are the sources of data. Furthermore, the preclinical in vitro and in vivo data, as well as efficacy and toxicity results of lenvatinib in the clinic, are presented and discussed. Treatment with lenvatinib causes side effects (hypertension, proteinuria, fatigue and diarrhea), which are predominantly related to the inhibition of angiogenesis. For these reasons, the identification of biomarkers of efficacy and resistance to lenvatinib is a key challenge in order to select responsive patients. This review provides an overview on lenvatinib’s clinical use, perspectives and indications for future development.

AB - Lenvatinib is an emerging multi-kinase inhibitor with a preferential antiangiogenic activity, which has shown efficacy in the treatment of renal cell carcinoma, differentiated thyroid cancer and hepatocellular carcinoma. It inhibits vascular endothelial growth factor receptor family (VEGFR1-3), fibroblast growth factor receptor family (FGFR1-4), platelet-derived growth factor receptor-alpha (PDGFRα), tyrosine-kinase receptor (KIT) and rearranged during transfection receptor (RET). In this review we have evaluated the development from bench to bedside of lenvatinib. PubMed, MEDLINE and clinicaltrials.gov are the sources of data. Furthermore, the preclinical in vitro and in vivo data, as well as efficacy and toxicity results of lenvatinib in the clinic, are presented and discussed. Treatment with lenvatinib causes side effects (hypertension, proteinuria, fatigue and diarrhea), which are predominantly related to the inhibition of angiogenesis. For these reasons, the identification of biomarkers of efficacy and resistance to lenvatinib is a key challenge in order to select responsive patients. This review provides an overview on lenvatinib’s clinical use, perspectives and indications for future development.

KW - Angiogenesis

KW - Kinase inhibitors

KW - Microvessel density

KW - Tumors

UR - http://www.scopus.com/inward/record.url?scp=85067075431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067075431&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S188316

DO - 10.2147/CMAR.S188316

M3 - Article

AN - SCOPUS:85067075431

VL - 11

SP - 3847

EP - 3860

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

ER -